Laurus Labs stock hit a record high of ₹1,530.30, marking a 53% gain in the first quarter of fiscal 2027. This rally follows the company’s strategic shift toward its CDMO business, which now contributes 30% of total revenue. Investors are monitoring the impact of ongoing expansion projects on future profit margins and operational efficiency.
What Happened
Laurus Labs recorded a 53% jump in its share price during the first quarter of fiscal year 2027 (Q1FY27). This performance pushed the stock to a record high of ₹1,530.30 on the BSE. The sharp rise in the share price follows market interest in the company’s shifting business model. Once heavily dependent on the high-volume but competitive antiretroviral (ARV) API market, the company has increasingly focused on its Contract Development and Manufacturing Organization (CDMO) segment. This pivot is central to the positive sentiment surrounding the stock, as investors assess the company’s ability to move toward higher-value manufacturing contracts.
The CDMO Growth Driver
The most significant change in the company's business structure is the rising importance of the CDMO segment. This part of the business now accounts for over 30% of total revenue, a sharp increase from 13% just six years ago. Conversely, the contribution from the ARV segment has fallen from 67% to 41% in fiscal year 2026. This transition is important because CDMO contracts often offer more stable and predictable revenue streams compared to commodity-based generic APIs, which can be sensitive to price fluctuations. In fiscal 2026, the CDMO (small molecule) segment generated ₹1,896 crore, representing a 38% growth rate driven by late-stage project pipelines and commercial API supply agreements.
Financial Performance And Margin Expansion
In fiscal year 2026, Laurus Labs reported revenue of ₹6,813 crore, reflecting a 23% increase compared to the previous year. The company managed to maintain gross margins near 60%, while EBITDA margins improved to 26.8%, a rise of 6.7 percentage points. This improvement suggests that the company is getting better at managing its costs while scaling up. The management is currently investing heavily in expansion projects that are expected to be completed within the next two years. These capital spending initiatives are designed to improve technology platforms and increase capacity to handle more complex manufacturing projects.
Risks And Execution Factors
While the growth in the CDMO business is a positive signal, investors should consider the inherent risks in this model. CDMO businesses rely heavily on the success of their clients' projects and regulatory approvals. If a client’s drug fails in clinical trials or faces commercial delays, the manufacturer’s revenue can be impacted. Additionally, the company is undertaking significant capital spending to expand its capacity. Any delay in setting up these new facilities or difficulties in getting them fully operational could lead to higher costs and lower-than-expected returns on investment. Like its peers in the Indian pharmaceutical sector, Laurus Labs also faces global competitive pressure, as other companies are also expanding their CDMO capabilities to cater to global pharmaceutical firms looking for alternatives to Chinese supply chains.
What Investors Should Track
Moving forward, the primary monitorables for shareholders include the progress of the company’s current expansion projects and their commissioning timelines. Investors will also look for management updates on order inflows, specifically whether the company can continue to win and execute contracts with large global pharmaceutical partners. Finally, maintaining EBITDA margins will remain a key test as the company scales up these newer, more complex operations and integrates its expanded capacity into the existing business.